These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 8715799)

  • 41. Conversion from Sandimmune to Neoral in renal transplant: functional histopathological, and pharmacokinetic changes.
    Roessler E; Herrera S; Espinoza M; Ayala A; Reynolds E; González F; Espinoza O; Undurraga A; Muñoz R; Arcos O; Galaz G
    Transplant Proc; 1998 Aug; 30(5):1756-7. PubMed ID: 9723268
    [No Abstract]   [Full Text] [Related]  

  • 42. Interim analysis of study OLN-356: Neoral versus Sandimmune in US primary liver transplant recipients. OLN-356 Principal Investigators.
    Pinson CW; Beauregard-Zollinger L
    Transplant Proc; 1996 Aug; 28(4):2234-6. PubMed ID: 8769209
    [No Abstract]   [Full Text] [Related]  

  • 43. Measurement of lymphocyte cyclosporine levels in transplant patients.
    Masri MA; Barbari A; Stephan A; Rizk S; Kilany H; Kamel G
    Transplant Proc; 1998 Nov; 30(7):3561-2. PubMed ID: 9838559
    [No Abstract]   [Full Text] [Related]  

  • 44. Optimization of cyclosporine therapy in kidney transplantation.
    Remuzzi G; Perico N; Gaspari F
    Transplant Proc; 1998 Aug; 30(5):1673-6. PubMed ID: 9723238
    [No Abstract]   [Full Text] [Related]  

  • 45. Cyclosporine A: peak or trough level monitoring in renal transplant recipients?
    Wacke R; Drewelow B; Kundt G; Hehl EM; Bast R; Seiter H
    Transplant Proc; 2001; 33(7-8):3122-3. PubMed ID: 11750342
    [No Abstract]   [Full Text] [Related]  

  • 46. Nine-month follow-up of SangCya (Sang-35) in kidney transplant patients after conversion from Sandimmune.
    First MR; Weiskittel P; Burton ML; Shah MB; Dreyer D; Fleck P; Bey C; Peddi VR; Canafax DM; Schroeder TJ
    Transplant Proc; 1999; 31(1-2):324-5. PubMed ID: 10083127
    [No Abstract]   [Full Text] [Related]  

  • 47. Conversion of stable renal transplant recipients from Sandimmune to Sang-35, a novel cyclosporine formulation, using a dose-normalized equivalence method.
    First MR; Weiskittel P; Burton M; Shah M; Dreyer D; Fleck P; Bey C; Peddi R; Canafax D; Schroeder TJ
    Transplant Proc; 1998 Aug; 30(5):1701-5. PubMed ID: 9723249
    [No Abstract]   [Full Text] [Related]  

  • 48. Time-dependent difference of the 12-hour trough levels of cyclosporine in renal transplant recipients with sandimmune capsule.
    To H; Haba T; Uchida K; Fujimura A; Kobayashi E
    Transplant Proc; 2000 Feb; 32(1):221-2. PubMed ID: 10701028
    [No Abstract]   [Full Text] [Related]  

  • 49. Lessons from the Neoral Global Database.
    Helderman JH
    Transplant Proc; 1998 Aug; 30(5):1721-2. PubMed ID: 9723255
    [No Abstract]   [Full Text] [Related]  

  • 50. Neoral as the initial immunosuppressant in liver transplantation; conversion from Sandimmune to Neoral in stable patients.
    Kizilisik AT; al-Sebayel M; Ramirez CB
    Transplant Proc; 1998 Nov; 30(7):3537-8. PubMed ID: 9838549
    [No Abstract]   [Full Text] [Related]  

  • 51. Usefulness of two-point AUC(0-4) monitoring in maintenance renal transplant patients.
    Uchida K; Tominaga Y; Haba T; Katayama A; Sato T; Matsuoka S; Goto N; Kimata T; Takeda A; Morozumi K; Takagi H; Kobayashi T; Yokoyama I; Nakao A
    Transplant Proc; 2001; 33(7-8):3128-30. PubMed ID: 11750345
    [No Abstract]   [Full Text] [Related]  

  • 52. Cyclosporine level: which single-point estimation of drug level is the best?
    Sharma R; Kumar J; Ahmed M; Gupta A; Gulati S; Sharma AP; Bhandari M
    Transplant Proc; 2001; 33(7-8):3124-5. PubMed ID: 11750343
    [No Abstract]   [Full Text] [Related]  

  • 53. Conversion of C-0 to C-2 monitoring of cyclosporine in stable kidney transplant patients.
    Jirasiritham S; Mavichak V; Danviriyasup K; Jirasiritham S
    Transplant Proc; 2003 Feb; 35(1):236-7. PubMed ID: 12591379
    [No Abstract]   [Full Text] [Related]  

  • 54. On realistic survival data, Neoral dosage.
    Hull AR
    Nephrol News Issues; 1996 Jan; 10(1):15-6. PubMed ID: 8709988
    [No Abstract]   [Full Text] [Related]  

  • 55. Feasibility of changing therapeutic cyclosporine monitoring from C(0) to C(2) in stable renal recipients: narrower coefficient of variation with C(2) monitoring.
    Chueh SC; Liao CH; Chang CJ; Lai MK
    Transplant Proc; 2001; 33(7-8):3100-1. PubMed ID: 11750332
    [No Abstract]   [Full Text] [Related]  

  • 56. Neoral-based immunosuppression in living-related donor liver transplantation.
    Liu PP; Chen CL; Chen YS; Wang CC; Chiang YC; Goto S; Cheng YF; Huang TL; Eng HL; Cheung HK; Jawan B
    Transplant Proc; 1998 Nov; 30(7):3550-1. PubMed ID: 9838554
    [No Abstract]   [Full Text] [Related]  

  • 57. Neoral: the new cyclosporine.
    Corbett J; Ross K
    ANNA J; 1998 Feb; 25(1):71-2. PubMed ID: 9543913
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cyclosporine (Sandimmune).
    Kosier JH; Phelps K; Newton M
    Urol Nurs; 1996 Sep; 16(3):112-3. PubMed ID: 9295806
    [No Abstract]   [Full Text] [Related]  

  • 59. [Cyclosporine].
    Yuhki Y; Tadano K
    Nihon Rinsho; 2004 Dec; 62 Suppl 12():461-4. PubMed ID: 15658363
    [No Abstract]   [Full Text] [Related]  

  • 60. Effect of cyclosporine intervariability on the long-term outcome of renal transplantation.
    Schreiber M; Hauser I; Brinker A; Renders L; Neumayer HH
    Transplant Proc; 1997; 29(1-2):274. PubMed ID: 9122992
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.